The Link Between Insulin Resistance and the Development of Heart Disease

The Link Between Insulin Resistance and the Development of Heart Disease
Metabolic dysregulations begin with unhealthy physical and dietary lifestyles (modifiable risk factors) and genetic predisposition (non-modifiable risk factors). ShutterStock
For Cardiovascular Diabetology’s 20th anniversary, we’ve asked the authors of the journal’s most influential articles to comment on their findings from today’s perspective and how the articles may have advanced science and influenced their careers. In this blog Carlos Salomon and colleagues discuss their article on the link between insulin resistance and the development of heart disease.
According to the International Diabetes Federation (IDF) in 2021 an estimated 537 million people had diabetes, and this is projected to rise to 642 million by 2040. Cardiovascular diseases (CVD) are the leading cause of death globally, claiming 17.3 million lives annually. By 2030 almost 23.6 million people may die from one of these conditions. The current data and projections are stark and call for stricter measures to combat this silent pandemic. Diabetes and CVD share a common denominator —BMCV metabolic dysregulations.

When do Metabolic Dysregulations Begin?

Metabolic dysregulations begin with unhealthy physical and dietary lifestyles (modifiable risk factors) and genetic predisposition (non-modifiable risk factors). Poor nutrition contributes to high blood lipids (hyperlipidemia) and insulin resistance that causes high blood sugar (hyperglycemia). Excess glucose in the blood alters metabolism and signaling in cells and negatively impacts several processes.
Associate Professor Carlos Salomon (BSc (Hons I), MPhil, DMedSc, PhD) is a worldwide expert in extracellular vesicles (EV) and gestational diabetes mellitus with over 140 publications, and over 8000 citations in the last 7 years. Dr. Salomon's research program has investigated the release of small EV(commonly known as exosomes) by the placenta and tumour cells during gestation and cancer progression, respectively, and their utility as a biomarker for a wide range of pregnancy complications and ovarian cancer.
Related Topics